ClinicalTrials.gg

Program

ABI-6250

A development code.

Its studies are mostly in Hepatitis D, Chronic · Hepatitis D, led by Assembly Biosciences.

Furthest: phase 2, since Aug 5, 20263 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Assembly Biosciences32 open or runningphase 2since Aug 5, 2026Dec 13, 2024Apr 2027phase 1 · NCT07850999

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2024First study: phase 1 study in Hepatitis DFirst studyNCT06740474 · 40 enrolled · New Zealand
  2. Aug 5, 2026Phase 2 study in Chronic Hepatitis D InfectionPhase 2 reachedNCT07762027 · 80 planned · France, Georgia, Germany and more
  3. Sep 14, 2026Phase 1 study in Mild Hepatic ImparementNCT07850999 · 20 planned · New Zealand

Ahead

  1. Apr 2027Primary completion: phase 1 study in Mild Hepatic ImparementNCT07850999
  2. Jun 2027Primary completion: phase 2 study in Chronic Hepatitis D InfectionNCT07762027

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07850999Mild Hepatic Imparement · New Zealand1Not yet recruitingApr 202720
NCT07762027Chronic Hepatitis D Infection · France, Georgia, Germany and more2Not yet recruitingJun 202780
NCT06740474Hepatitis D · New Zealand1CompletedJul 8, 202540

How it is read

Names in the registry

  • “ABI-6250”, 4 entries

Codes read as this program: ABI6250.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.